Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study-Reference-Cited by-同舟云学术

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study

Published:2020-01 Issue:1 Volume:104 Page:154-164
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Gustafsson Finn,Andreassen Arne K.,Andersson Bert,Eiskjær Hans,Rådegran Göran,Gude Einar,Jansson Kjell,Solbu Dag,Karason Kristjan,Arora Satish,Dellgren Göran,Gullestad Lars

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference43 articles.

1. Natural course and risk factors for impaired renal function during the first year after heart transplantation.;Jokinen;J Heart Lung Transplant,2010

2. Renal function and outcome after heart transplantation.;Kolsrud;J Thorac Cardiovasc Surg,2018

3. Metabolic syndrome in heart transplantation: impact on survival and renal function.;Martínez-Dolz;Transpl Int,2013

4. Risk factors for chronic renal insufficiency following cardiac transplantation.;Lachance;Ann Transplant,2015

5. The registry of the international society for heart and lung transplantation: thirty-first official adult heart transplant report–2014; focus theme: retransplantation.;Lund;J Heart Lung Transplant,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ten-year follow-up cohort of the everolimus versus azathioprine multinational prospective study focusing on intravascular ultrasound findings;The Journal of Heart and Lung Transplantation;2024-07

2. Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial;The Journal of Heart and Lung Transplantation;2024-07

3. mTor‐inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy;Pediatric Transplantation;2024-03

4. Advances in the regulatory mechanisms of mTOR in necroptosis;Frontiers in Immunology;2023-12-18

5. Drug levels after sirolimus initiation and short‐term outcomes in ambulatory heart transplantation recipients;Clinical Transplantation;2023-11-07